Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
    • UDDA Revision Series
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
    • UDDA Revision Series
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

April 10, 2018; 90 (15 Supplement) April 23, 2018

Safety profile of abobotulinumtoxinA (Dysport®) for lower limb spasticity: Pooled analysis of controlled clinical trials (P2.323)

Ann Tilton, Dennis Matthews, Mark Gormley, Gustavo Suarez, Philippe Picaut, Mauricio Delgado
First published April 9, 2018,
Ann Tilton
1LSUHSC and Childrens Hospital of New Orleans New Orleans LA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dennis Matthews
2Children’s Hospital Colorado Aurora CO United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Gormley
3Gillette Children’s Specialty Healthcare St Paul MN United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gustavo Suarez
4Ipsen Biopharmaceuticals Basking Ridge NJ United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philippe Picaut
5Ipsen Pharma Les Ulis France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mauricio Delgado
6Texas Scottish Rite Hospital for Children Dallas TX United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Safety profile of abobotulinumtoxinA (Dysport®) for lower limb spasticity: Pooled analysis of controlled clinical trials (P2.323)
Ann Tilton, Dennis Matthews, Mark Gormley, Gustavo Suarez, Philippe Picaut, Mauricio Delgado
Neurology Apr 2018, 90 (15 Supplement) P2.323;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: To review pediatric safety data from randomized controlled trials of abobotulinumtoxinA by age group.

Background: AbobotulinumtoxinA has recently been approved for the treatment of lower limb spasticity in children aged 2 years and older.

Design/Methods: This was a pooled analysis of safety data from 4 controlled clinical trials of abobotulinumtoxinA in children aged 2–17 years old with lower limb spasticity due to cerebral palsy. Individual adverse event (AE) data for each study were pooled to form one database. Descriptive pooled safety data are presented for preschool aged children (aged 2–5 years) and older children (elementary school [6–9 years old] and middle/high school [10+ years]).

Results: The preschool group included 299 children aged 2–5 years (abobotulinumtoxinA=195, placebo=104), the elementary-school group included 134 children aged 6–9 years (abobotulinumtoxinA =87, placebo=47) and the middle/high-school group included 43 children aged 10+ years (abobotulinumtoxinA=30, placebo=13). Across all age groups most AEs were related to childhood illness (e.g. respiratory tract infection, nasopharyngitis, pyrexia); rates of AEs (abobotulinumtoxinA vs. placebo) were: Preschool (60.5% Vs 52.9%), elementary-school (58.6% Vs 36.2%), middle/high-school (40.0% Vs 46.2%). Rates of TEAEs considered related to abobotulinumtoxinA treatment were low across all age groups: Preschool (14.9% Vs 8.7%), elementary-school (11.5% Vs 2.1%), middle/high-school (6.7% Vs 15.4%). Serious AEs were reported in 10 preschool aged children (n=5 in both groups), 4 elementary-school aged children (abobotulinumtoxinA =3, placebo=1) and 1 middle/high school aged child (abobotulinumtoxinA =1). Of these, the only serious AE considered to be treatment related occurred in the middle/high school aged child (moderate dysarthria & moderate muscular weakness following injection of 30U/kg in hamstrings & adductor muscles). This was also the only treatment-related AE that led to premature study withdrawal. No unexpected AEs were reported in any age group.

Conclusions: These analyses indicate a consistently well-tolerated profile of abobotulinumtoxinA across age groups.

Study Supported by: Ipsen Pharma

Disclosure: Dr. Tilton has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ipsen Pharma. Dr. Tilton has received research support from Ipsen Pharma. Dr. Matthews has received research support from Ipsen Pharma. Dr. Gormley has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ipsen Pharma. Dr. Gormley has received research support from Ipsen Pharma. Dr. Suarez-Zambrano has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ipsen. Dr. Picaut has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ipsen. Dr. Delgado has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ipsen Pharma. Dr. Delgado has received research support from Ipsen Pharma.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Association Between Fluctuations in Blood Lipid Levels Over Time With Incident Alzheimer Disease and Alzheimer Disease–Related Dementias

Dr. Sevil Yaşar and Dr. Behnam Sabayan

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 101 (14)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise